These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29216560)

  • 1. Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2.
    Yuan MC; Yeh TK; Chen CT; Song JS; Huang YC; Hsieh TC; Huang CY; Huang YL; Wang MH; Wu SH; Yao CH; Chao YS; Lee JC
    Eur J Med Chem; 2018 Jan; 143():611-620. PubMed ID: 29216560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Meng W; Ellsworth BA; Nirschl AA; McCann PJ; Patel M; Girotra RN; Wu G; Sher PM; Morrison EP; Biller SA; Zahler R; Deshpande PP; Pullockaran A; Hagan DL; Morgan N; Taylor JR; Obermeier MT; Humphreys WG; Khanna A; Discenza L; Robertson JG; Wang A; Han S; Wetterau JR; Janovitz EB; Flint OP; Whaley JM; Washburn WN
    J Med Chem; 2008 Mar; 51(5):1145-9. PubMed ID: 18260618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 6-deoxydapagliflozin as a highly potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Zhang L; Wang Y; Xu H; Shi Y; Liu B; Wei Q; Xu W; Tang L; Wang J; Zhao G
    Med Chem; 2014 May; 10(3):304-17. PubMed ID: 24059684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
    Wan HX; Shen JK
    Yao Xue Xue Bao; 2012 Jun; 47(6):716-24. PubMed ID: 22919717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
    Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors.
    Chu KF; Song JS; Chen CT; Yeh TK; Hsieh TC; Huang CY; Wang MH; Wu SH; Yao CH; Chao YS; Lee JC
    Bioorg Chem; 2019 Mar; 83():520-525. PubMed ID: 30469144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
    Simonyi G
    Orv Hetil; 2012 May; 153(18):695-701. PubMed ID: 22547464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
    Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
    J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors.
    Xu G; Gaul MD; Kuo GH; Du F; Xu JZ; Wallace N; Hinke S; Kirchner T; Silva J; Huebert ND; Lee S; Murray W; Liang Y; Demarest K
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3446-3453. PubMed ID: 30268701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
    Komoroski B; Vachharajani N; Boulton D; Kornhauser D; Geraldes M; Li L; Pfister M
    Clin Pharmacol Ther; 2009 May; 85(5):520-6. PubMed ID: 19129748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
    Demaris KM; White JR
    Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural selectivity of human SGLT inhibitors.
    Hummel CS; Lu C; Liu J; Ghezzi C; Hirayama BA; Loo DD; Kepe V; Barrio JR; Wright EM
    Am J Physiol Cell Physiol; 2012 Jan; 302(2):C373-82. PubMed ID: 21940664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
    Wang MY; Yu X; Lee Y; McCorkle SK; Chen S; Li J; Wang ZV; Davidson JA; Scherer PE; Holland WL; Unger RH; Roth MG
    Proc Natl Acad Sci U S A; 2017 Jun; 114(25):6611-6616. PubMed ID: 28584109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
    Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
    J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
    Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
    Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Calado J
    IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.